NASDAQ:SRPT - Sarepta Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$91.65 +1.66 (+1.84 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$91.65
Today's Range$90.15 - $92.05
52-Week Range$28.82 - $95.67
Volume884,786 shs
Average Volume1.48 million shs
Market Capitalization$5.83 billion
P/E Ratio-55.88
Dividend YieldN/A
Beta1.34

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000

Debt

Debt-to-Equity Ratio0.55
Current Ratio13.37
Quick Ratio12.28

Price-To-Earnings

Trailing P/E Ratio-55.88
Forward P/E Ratio-47.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$154.58 million
Price / Sales38.85
Cash FlowN/A
Price / CashN/A
Book Value$11.85 per share
Price / Book7.73

Profitability

EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-83.88%
Return on Equity-24.68%
Return on Assets-16.89%

Miscellaneous

Employees255
Outstanding Shares65,530,000

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.23. The biotechnology company earned $64.60 million during the quarter, compared to analysts' expectations of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. Sarepta Therapeutics's quarterly revenue was up 295.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.57) EPS. View Sarepta Therapeutics' Earnings History.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Sarepta Therapeutics.

What price target have analysts set for SRPT?

20 brokerages have issued 12-month target prices for Sarepta Therapeutics' shares. Their predictions range from $56.51 to $131.00. On average, they expect Sarepta Therapeutics' stock price to reach $94.1911 in the next year. View Analyst Ratings for Sarepta Therapeutics.

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:
  • Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 53)
  • Mr. David Tyronne Howton Jr., Sr. VP, Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Alexander Bo Cumbo, Sr. VP & Chief Commercial Officer (Age 47)
  • Ms. Shamim Ruff, Sr. VP & Chief Regulatory Affairs Officer (Age 58)
  • Dr. Edward M. Kaye, Advisor (Age 69)

Has Sarepta Therapeutics been receiving favorable news coverage?

News coverage about SRPT stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.25%), Eagle Asset Management Inc. (1.49%), JPMorgan Chase & Co. (1.08%), OppenheimerFunds Inc. (0.76%), Element Capital Management LLC (0.62%) and Lord Abbett & CO. LLC (0.61%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, BlackRock Inc., Lord Abbett & CO. LLC, Sphera Funds Management LTD., Oak Ridge Investments LLC, C WorldWide Group Holding A S, PNC Financial Services Group Inc. and Nuveen Asset Management LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, JPMorgan Chase & Co., Franklin Resources Inc., Dimensional Fund Advisors LP, Element Capital Management LLC, Eventide Asset Management LLC, Sector Gamma AS and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $91.65.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $5.83 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  939 (Vote Outperform)
Underperform Votes:  591 (Vote Underperform)
Total Votes:  1,530
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sarepta Therapeutics (NASDAQ:SRPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Sarepta Therapeutics in the last 12 months. Their average twelve-month price target is $94.1911, suggesting that the stock has a possible upside of 2.77%. The high price target for SRPT is $131.00 and the low price target for SRPT is $56.51. There are currently 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.852.892.902.79
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $94.1911$82.5906$68.2255$65.6111
Price Target Upside: 2.77% upside3.25% upside8.52% upside37.72% upside

Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History

Price Target History for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Goldman Sachs GroupBoost Price TargetBuy$84.00 ➝ $127.00LowView Rating Details
5/15/2018Leerink SwannBoost Price TargetHold ➝ Outperform$88.00 ➝ $121.00LowView Rating Details
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$55.00 ➝ $107.00LowView Rating Details
5/7/2018Needham & Company LLCBoost Price TargetIn-Line ➝ Buy$75.00 ➝ $109.00LowView Rating Details
5/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$87.00 ➝ $91.00HighView Rating Details
5/4/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$100.00 ➝ $92.00HighView Rating Details
5/4/2018NomuraBoost Price TargetBuy$131.00HighView Rating Details
5/4/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$98.00HighView Rating Details
5/4/2018JMP SecuritiesReiterated RatingOutperform$95.00 ➝ $90.00HighView Rating Details
5/4/2018HC WainwrightSet Price TargetBuy ➝ Buy$90.00 ➝ $96.00HighView Rating Details
5/4/2018OppenheimerDowngradeOutperform ➝ Market PerformHighView Rating Details
5/4/2018UBSDowngradeOutperform ➝ Market PerformHighView Rating Details
3/16/2018SunTrust BanksBoost Price TargetBuy$95.00MediumView Rating Details
3/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$75.00 ➝ $95.00LowView Rating Details
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight$83.00 ➝ $76.12HighView Rating Details
2/5/2018William BlairReiterated RatingOutperformHighView Rating Details
1/3/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00MediumView Rating Details
10/17/2017Robert W. BairdReiterated RatingBuy$101.00N/AView Rating Details
10/2/2017InstinetReiterated RatingBuy$84.00LowView Rating Details
9/14/2017CowenReiterated RatingOutperform$69.00MediumView Rating Details
4/6/2017Jefferies GroupReiterated RatingHold$27.00MediumView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 ➝ $60.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Sarepta Therapeutics (NASDAQ:SRPT) Earnings History and Estimates Chart

Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.45)($0.38)($0.40)
Q2 20183($0.42)($0.30)($0.35)
Q3 20183($0.31)($0.25)($0.28)
Q4 20183($0.19)($0.15)($0.16)

Sarepta Therapeutics (NASDAQ SRPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/17/2018($0.63)N/AView Earnings Details
5/3/2018Q1 2018($0.32)($0.55)$65.31 million$64.60 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.32)($0.37)$57.33 million$57.30 millionViewListenView Earnings Details
10/25/2017Q3 2017($0.86)($0.20)$41.29 million$45.95 millionViewN/AView Earnings Details
7/19/2017Q2 2017($0.92)($0.46)$22.52 million$35.01 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.1920)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.29)($0.24)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.42)($0.30)ViewN/AView Earnings Details
3/1/2012Q4 2011($0.36)($0.06)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.30)($0.18)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.42)$0.05ViewN/AView Earnings Details
5/5/2011Q1 2011($0.18)$0.12ViewN/AView Earnings Details
3/10/2011Q4 2010($0.42)($0.41)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.36)($0.42)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.30)($0.91)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.24)($0.03)ViewN/AView Earnings Details
3/16/2010Q4 2009($0.36)$0.18ViewN/AView Earnings Details
11/9/2009Q3 2009($0.42)($0.48)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.12)($0.36)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.18)($0.07)ViewN/AView Earnings Details
3/10/2009Q4 2008($0.30)($0.10)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.42)($0.50)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.42)($0.14)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.78)($0.47)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.45)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sarepta Therapeutics (NASDAQ:SRPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 86.32%
Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Hans Lennart Rudolf WigzellDirectorSell6,667$55.89$372,618.6313,333View SEC Filing  
11/8/2017Douglas S IngramCEOBuy38,138$52.44$1,999,956.72420,196View SEC Filing  
11/6/2017Shamim RuffSVPSell10,000$55.00$550,000.0037,045View SEC Filing  
10/3/2017Shamim RuffSVPSell11,500$50.00$575,000.00View SEC Filing  
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00382,058View SEC Filing  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.8627,312View SEC Filing  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.0022,793View SEC Filing  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.0062,471View SEC Filing  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.0041,736View SEC Filing  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.0061,532View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.0028,453View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00117,162View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.0011,168View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.0089,983View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.0021,490View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.0076,983View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00112,166View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00112,166View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.0041,744View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.0044,166View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.0031,744View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.005,000View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sarepta Therapeutics (NASDAQ SRPT) News Headlines

Source:
DateHeadline
Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD DrugSarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug
www.thestreet.com - May 25 at 6:10 PM
Wave Life Sciences: Whats Cooking Behind This Innovator?Wave Life Sciences: What's Cooking Behind This Innovator?
seekingalpha.com - May 23 at 8:07 AM
Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC CapitalSarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital
www.streetinsider.com - May 18 at 6:19 PM
Sarepta Therapeutics (SRPT) PT Raised to $127.00Sarepta Therapeutics (SRPT) PT Raised to $127.00
www.americanbankingnews.com - May 18 at 5:07 PM
$70.92 Million in Sales Expected for Sarepta Therapeutics (SRPT) This Quarter$70.92 Million in Sales Expected for Sarepta Therapeutics (SRPT) This Quarter
www.americanbankingnews.com - May 17 at 3:46 AM
Should Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Recent Earnings Decline Worry You?Should Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Recent Earnings Decline Worry You?
finance.yahoo.com - May 16 at 6:00 PM
Sarepta Therapeutics (SRPT) Receives Outperform Rating from Leerink SwannSarepta Therapeutics (SRPT) Receives Outperform Rating from Leerink Swann
www.americanbankingnews.com - May 15 at 2:26 PM
-$0.57 Earnings Per Share Expected for Sarepta Therapeutics (SRPT) This Quarter-$0.57 Earnings Per Share Expected for Sarepta Therapeutics (SRPT) This Quarter
www.americanbankingnews.com - May 15 at 1:39 PM
These 3 Stocks Have Doubled Investors' MoneyThese 3 Stocks Have Doubled Investors' Money
finance.yahoo.com - May 15 at 8:06 AM
Sarepta Therapeutics (SRPT) Given Consensus Recommendation of "Buy" by BrokeragesSarepta Therapeutics (SRPT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 1:49 PM
Barclays Upgrades Sarepta Therapeutics (SRPT) to "Overweight"Barclays Upgrades Sarepta Therapeutics (SRPT) to "Overweight"
www.americanbankingnews.com - May 11 at 6:33 PM
UPDATE: Barclays Upgrades Sarepta Therapeutics (SRPT) to OverweightUPDATE: Barclays Upgrades Sarepta Therapeutics (SRPT) to Overweight
www.streetinsider.com - May 11 at 6:19 PM
Nationwide Childrens gene therapy spinoff raises up to $105M, with option to be acquiredNationwide Children's gene therapy spinoff raises up to $105M, with option to be acquired
www.bizjournals.com - May 8 at 8:03 AM
Sarepta Therapeutics Reaches Analyst Target PriceSarepta Therapeutics Reaches Analyst Target Price
www.nasdaq.com - May 7 at 5:50 PM
The Market Has Spoken: Buy SareptaThe Market Has Spoken: Buy Sarepta
seekingalpha.com - May 7 at 5:50 PM
Sarepta Therapeutics (SRPT) PT Raised to $109.00 at Needham & Company LLCSarepta Therapeutics (SRPT) PT Raised to $109.00 at Needham & Company LLC
www.americanbankingnews.com - May 7 at 2:58 PM
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & CompanySarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
www.streetinsider.com - May 7 at 8:07 AM
Sarepta Wont Let One Stumble Bring It DownSarepta Won't Let One Stumble Bring It Down
seekingalpha.com - May 7 at 8:07 AM
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular DystrophySarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
finance.yahoo.com - May 7 at 8:07 AM
Edited Transcript of SRPT earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of SRPT earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 5 at 6:00 PM
Sarepta not quite there with Exondys 51 approval in EuropeSarepta not quite there with Exondys 51 approval in Europe
seekingalpha.com - May 5 at 8:04 AM
Sarepta Raises New HopesSarepta Raises New Hopes
www.barrons.com - May 5 at 8:04 AM
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the ...Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the ...
globenewswire.com - May 5 at 8:04 AM
The Biotech Just Broke Out On Hype Surrounding Its Muscle Disease DrugsThe Biotech Just Broke Out On Hype Surrounding Its Muscle Disease Drugs
finance.yahoo.com - May 5 at 8:03 AM
[$$] Sarepta Raises New Hopes[$$] Sarepta Raises New Hopes
finance.yahoo.com - May 5 at 8:03 AM
Sarepta Therapeutics (SRPT) Price Target Cut to $92.00Sarepta Therapeutics (SRPT) Price Target Cut to $92.00
www.americanbankingnews.com - May 5 at 2:07 AM
Sarepta Therapeutics (SRPT) Price Target Raised to $91.00 at Morgan StanleySarepta Therapeutics (SRPT) Price Target Raised to $91.00 at Morgan Stanley
www.americanbankingnews.com - May 5 at 2:05 AM
Oppenheimer Lowers Sarepta Therapeutics (SRPT) to Market PerformOppenheimer Lowers Sarepta Therapeutics (SRPT) to Market Perform
www.americanbankingnews.com - May 4 at 11:27 PM
Sarepta Therapeutics (SRPT) Given a $90.00 Price Target at HC WainwrightSarepta Therapeutics (SRPT) Given a $90.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 4 at 10:33 PM
Sarepta Therapeutics (SRPT) PT Raised to $131.00 at NomuraSarepta Therapeutics (SRPT) PT Raised to $131.00 at Nomura
www.americanbankingnews.com - May 4 at 10:31 PM
Sarepta Therapeutics (SRPT) PT Raised to $98.00Sarepta Therapeutics (SRPT) PT Raised to $98.00
www.americanbankingnews.com - May 4 at 6:01 PM
Sarepta Therapeutics (SRPT) Rating Reiterated by JMP SecuritiesSarepta Therapeutics (SRPT) Rating Reiterated by JMP Securities
www.americanbankingnews.com - May 4 at 6:00 PM
Why Sarepta Therapeutics Is Soaring TodayWhy Sarepta Therapeutics Is Soaring Today
finance.yahoo.com - May 4 at 5:49 PM
Sarepta Shares Hit 52-Week High on Hopes for New DrugsSarepta Shares Hit 52-Week High on Hopes for New Drugs
finance.yahoo.com - May 4 at 5:49 PM
UBS Downgrades Sarepta Therapeutics (SRPT) to Market PerformUBS Downgrades Sarepta Therapeutics (SRPT) to Market Perform
www.americanbankingnews.com - May 4 at 3:17 PM
Sarepta Q1 Exondys 51 sales $64.6M (+296%); shares down 6% after hours on slight consensus missSarepta Q1 Exondys 51 sales $64.6M (+296%); shares down 6% after hours on slight consensus miss
seekingalpha.com - May 4 at 8:05 AM
Sarepta Therapeutics (SRPT) CEO Doug Ingram on Q1 2018 Results - Earnings Call TranscriptSarepta Therapeutics' (SRPT) CEO Doug Ingram on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:05 AM
Sarepta Therapeutics (SRPT) Posts  Earnings Results, Beats Estimates By $0.04 EPSSarepta Therapeutics (SRPT) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 10:29 PM
BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus TherapeuticsBRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics
www.reuters.com - May 3 at 5:36 PM
Sarepta Therapeutics: 1Q Earnings SnapshotSarepta Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:36 PM
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular DystrophiesSarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies
finance.yahoo.com - May 3 at 5:36 PM
Sarepta Therapeuticals shares down 5% after company misses Q1 expectationsSarepta Therapeuticals shares down 5% after company misses Q1 expectations
finance.yahoo.com - May 3 at 5:36 PM
Sarepta Therapeutics (SRPT) Upgraded to "Strong-Buy" at ValuEngineSarepta Therapeutics (SRPT) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
Zacks: Analysts Expect Sarepta Therapeutics (SRPT) Will Announce Quarterly Sales of $65.25 MillionZacks: Analysts Expect Sarepta Therapeutics (SRPT) Will Announce Quarterly Sales of $65.25 Million
www.americanbankingnews.com - April 30 at 7:25 AM
 Brokerages Anticipate Sarepta Therapeutics Inc (SRPT) Will Post Earnings of -$0.32 Per Share Brokerages Anticipate Sarepta Therapeutics Inc (SRPT) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 28 at 1:18 AM
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem — Discovering Underlying Factors of Influence
finance.yahoo.com - April 27 at 8:09 AM
Sarepta Therapeutics (SRPT) Scheduled to Post Earnings on ThursdaySarepta Therapeutics (SRPT) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 26 at 4:22 AM
Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and ...Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and ...
globenewswire.com - April 24 at 8:07 AM
Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018
finance.yahoo.com - April 23 at 5:23 PM
Sarepta Therapeutics (SRPT) Receives "Buy" Rating from HC WainwrightSarepta Therapeutics (SRPT) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - April 23 at 7:40 AM

SEC Filings

Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.